Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2008 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00085397
First received: June 10, 2004
Last updated: February 6, 2009
Last verified: April 2008

June 10, 2004
February 6, 2009
March 2004
Not Provided
Immune response [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00085397 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
A Randomized Phase II Study of Immunization Against Melanoma Comparing Autologous Dendritic Cells Pulsed With gp100 Peptide to Autologous Dendritic Cells Fused With Autologous Tumor Cells

RATIONALE: Vaccines made from a patient's dendritic cells may make the body build an immune response to kill tumor cells. It is not yet known whether combining vaccine therapy with either gp100 antigen or the patient's tumor cells will cause a stronger immune response and kill more tumor cells.

PURPOSE: This randomized phase II trial is studying vaccine therapy and gp100 antigen to see how well they work compared to vaccine therapy and patient's tumor cells in treating patients with stage III or stage IV melanoma.

OBJECTIVES:

Primary

  • Compare the tumor-specific immune response, in terms of the number of gp100-specific cytotoxic T-lymphocytes, T-cell production of interferon gamma, or T-cell proliferation in response to in vitro exposure to gp100 and tumor lysate, in patients with stage III or IV melanoma treated with autologous dendritic cells (DC) pulsed with gp100 antigen vs autologous DC fused with autologous tumor cells.

Secondary

  • Compare the safety and toxicity of these regimens in these patients.
  • Compare the therapeutic effect of these regimens in these patients.

OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

All patients undergo leukapheresis. Peripheral blood mononuclear cells are cultured to generate dendritic cells (DC).

  • Arm I: Patients undergo surgical harvesting of tumor cells for subsequent fusion. Patients receive vaccination comprising DC fused with autologous tumor cells subcutaneously on day 1. Treatment repeats every 21 days for 3 courses. Patients who achieve a partial (PR) or complete response (CR) may receive an additional 3 courses.
  • Arm II: Patients receive vaccination comprising DC pulsed with gp100 antigen IV on day 1. Treatment repeats every 21 days for 6 courses. Patients who achieve a PR or CR may receive an additional 6 courses.

In both arms, patients are followed monthly for 6 months.

PROJECTED ACCRUAL: A total of 40 patients (20 per treatment arm) will be accrued for this study.

Interventional
Phase 2
Allocation: Randomized
Primary Purpose: Treatment
Melanoma (Skin)
  • Biological: autologous dendritic cell-tumor fusion vaccine
    Given subcutaneously
  • Biological: gp100 antigen
    Given IV
  • Biological: therapeutic autologous dendritic cells
    Given IV
  • Experimental: Arm I
    Patients undergo surgical harvesting of tumor cells for subsequent fusion. Patients receive vaccination comprising dendritic cells (DC) fused with autologous tumor cells subcutaneously on day 1. Treatment repeats every 21 days for 3 courses. Patients who achieve a partial (PR) or complete response (CR) may receive an additional 3 courses.
    Intervention: Biological: autologous dendritic cell-tumor fusion vaccine
  • Experimental: Arm II
    Patients receive vaccination comprising DC pulsed with gp100 antigen IV on day 1. Treatment repeats every 21 days for 6 courses. Patients who achieve a PR or CR may receive an additional 6 courses.
    Interventions:
    • Biological: gp100 antigen
    • Biological: therapeutic autologous dendritic cells
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically confirmed cutaneous melanoma

    • Stage III or IV disease
    • Recurrent or de novo stage III disease allowed if disease is unresectable and no definitive treatment is available
  • gp100- and HLA-A201-positive
  • Surgically accessible tumor, defined by 1 of the following:

    • Pulmonary lesions approachable by thoracoscopic procedure
    • Skin or superficial soft tissue or lymph node lesions amenable to resection under local anesthesia
    • Malignant ascites or pleural effusion
  • Measurable disease in addition to surgically accessible tumor > 2.0 cm
  • No CNS metastases
  • No mucosal or ocular melanoma

PATIENT CHARACTERISTICS:

Age

  • Any age

Performance status

  • ECOG 0-1

Life expectancy

  • More than 3 months

Hematopoietic

  • WBC > 3,000/mm^3
  • Platelet count > 75,000/mm^3

Hepatic

  • Bilirubin < 2.0 mg/dL

Renal

  • Creatinine < 2.0 mg/dL

Immunologic

  • No active infection requiring treatment
  • No clinically significant autoimmune disorder
  • No immune deficiency disorder
  • HIV negative

Other

  • Antecubital vein accessible for leukapheresis
  • No other malignancy within the past 5 years except nonmelanoma skin cancer or squamous cell carcinoma in situ of the cervix
  • No pre-existing comorbid disease that would preclude study compliance
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • No prior melanoma vaccine therapy
  • More than 6 weeks since prior immunotherapy

Chemotherapy

  • No prior chemotherapy for metastatic melanoma

Endocrine therapy

  • No concurrent corticosteroids

Radiotherapy

  • More than 6 weeks since prior radiotherapy

Surgery

  • Not specified

Other

  • No concurrent systemic immunosuppressive therapy
Both
Not Provided
No
United States
 
NCT00085397
CDR0000369699, DFCI-03123
Not Provided
Not Provided
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Principal Investigator: Frank Haluska, MD, PhD Massachusetts General Hospital
Principal Investigator: David Avigan, MD Beth Israel Deaconess Medical Center
National Cancer Institute (NCI)
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP